Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US9579382B2 · kind B2 · utility
5Cited by
22References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 3, 2008 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Jul 6, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.